Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-17
    E.g., 2018-08-17

Articles

Pages

26781 items
10:24 AM, Aug 17, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
10:24 AM, Aug 17, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

ViiV Healthcare Ltd. (Brentford, U.K.) and Johnson & Johnson (NYSE:JNJ) said a two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults...
8:15 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Realm's atopic dermatitis candidate misses in Phase II

Realm Therapeutics plc (LSE:RLM; NASDAQ:RLM) reported preliminary data from a Phase II trial in 122 patients with mild to moderate atopic dermatitis showing that PR022 missed the primary endpoint. Twice-daily topical PR022 for 28 days...
8:15 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

RegenxBio's AMD gene therapy well tolerated in Phase I

RegenxBio Inc. (NASDAQ:RGNX) said a single subretinal injection of RGX-314 was well tolerated with no treatment-related serious adverse events reported in a Phase I trial to treat wet age-related macular degeneration (AMD). RGX-314 is an...
8:14 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

United Therapeutics' Orenitram delays disease progression in Phase III for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III FREEDOM-EV trial in 690 pulmonary arterial hypertension (PAH) patients on background oral monotherapy. Thrice-daily oral Orenitram significantly delayed...
8:14 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were "an unfortunate consequence...
8:14 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said RXI-109 was well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported in the Phase I/II RXI-109-1501 trial in nine patients with advanced neovascular age-related macular degeneration (AMD)...
8:13 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the...
8:13 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of...
8:12 PM, Aug 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first...

Pages